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Objective: Endothelin plays a role in the regulation of basal coronary tone. We
hypothesized that low coronary reflow and reduced cardiac function after prolonged
ischemia may be due to increased release of endogenous endothelin.
Methods: Using an isolated perfused rat heart, we examined the effect of the addi-
tion of various endothelin antagonists during reperfusion after 4 hours of cardio-
plegic arrest at 4°C. Hearts were freeze-clamped at the end of reperfusion for analy-
sis of high-energy phosphate levels. Results are expressed as the percentages of
preischemic values.
Results: The addition of bosentan or Ro61-0612 (nonselective endothelin antago-
nists) resulted in a significant increase in the recovery of coronary flow after 30
minutes of reperfusion (100.9% vs 85.3% [P = .03] and 122.4% vs 83.7% [P <
.001], respectively, versus controls). The addition of PD155080 (endothelin A
antagonist) had a similar effect (129.5% vs 91.4%, P = .008). BQ788 (endothelin B
antagonist) and phosphoramidon (endothelin-converting enzyme inhibitor) had no
effect. Myocardial adenosine triphosphate levels were significantly (12.1%) higher
after reperfusion with Ro61-0612 (18.1 ± 0.4 µmol/g vs 16.2 ± 0.5 µmol/g, P = .01).
There was no difference in the recovery of cardiac mechanical function with any of
the antagonists studied.
Conclusion: These results suggest that endogenous endothelin plays a role in low
coronary reflow after prolonged cardioplegic arrest but does not impair recovery of
myocardial function.
The endothelium plays a major role in the maintenance of vasculartone through the production and metabolism of various vasodilatingand vasoconstricting substances, including nitric oxide and endothe-lin (ET). We have recently demonstrated that endogenous release ofET plays an important role in basal coronary tone in the rat.1Ischemia-reperfusion injury results in a decrease in cardiac function
and reduced coronary flow (CF; or low coronary reflow). It has been shown the vas-
cular endothelium plays an important role in low coronary reflow through the
release of various vasoactive substances, particularly nitric oxide.2-4
Previous studies using models of warm ischemia have shown that ET levels are
elevated after myocardial infarction and that ET antagonists and monoclonal anti-
bodies to ET can reduce the size of infarction.5-9 However, other studies have found
no effect of ET antagonists on the size of infarction or on the recovery of cardiac
function after ischemia.10,11 We have shown previously that inhibition of ET during
cold ischemia, by means of the addition of antagonists to cardioplegic solution, can
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be beneficial in the recovery of postischemic CF in a proto-
col mimicking the conditions of preservation during cardiac
operations and transplantation.12 However, there was no
benefit in the recovery of cardiac mechanical function. To
date, there are no studies of the role of endogenous ET in
low coronary reflow after hypothermic or prolonged
ischemia.
In view of the uncertainty of the role of ET during reper-
fusion, and in particular during prolonged cardioplegic
arrest, the aim of this study was to examine the role of
endogenous ET in the postischemic reduction of CF and
cardiac function.
Material and Methods
Animals
Male Sprague-Dawley rats weighing 300 to 330 g were used in all
experiments. In all studies, animals received humane care in com-
pliance with the “Principles of Laboratory Animal Care” formulat-
ed by the National Society for Medical Research and the “Guide
for the Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press, revised
1996.
Experimental Preparation
The isolated working rat heart preparation was used in this study,
as has already been described in detail elsewhere.12,13 In brief, the
animals were put to death by means of cervical dislocation. The
femoral vein was immediately exposed, and heparin (200 IU) was
injected. The heart was then excised and immediately placed in
ice-cold (4°C) Krebs solution. The aorta was rapidly cannulated
(within approximately 30 seconds), and Langendorff perfusion
was initiated. The hearts were perfused with Krebs-Henseleit
bicarbonate buffer consisting of the following: NaCl, 118.5
mmol/L; NaHCO3, 25.0 mmol/L; KCl, 4.8 mmol/L; MgSO4, 1.2
mmol/L; KH2PO4, 1.2 mmol/L; CaCl2, 2.25 mmol/L; and glucose,
11.0 mmol/L. The buffer is continuously gassed with 95% oxygen
and 5% carbon dioxide, maintained at 37°C and pH 7.4, and flows
from a reservoir 100 cm above the heart.
In the hearts used in the working mode, the left atrium is then
cannulated. An incision is also made in the pulmonary artery to
ensure ejection of the coronary sinus effluent. After an initial peri-
od of Langendorff perfusion, the heart is switched over to the
working mode. The left atrium is perfused at a constant pressure of
15 cm H2O from a reservoir 15 cm above the atrial cannula. The
heart then spontaneously ejects the perfusion fluid through the aor-
tic cannula against a pressure of 100 cm H2O (the height of the aor-
tic flow [AF] line). The heart is suspended in a water-jacketed
chamber maintained at 37°C.
CF during Langendorff perfusion was monitored with an in-
line electromagnetic flow probe (ECM2 20 mL; Scalar, Delft,
Holland) connected to its compatible flowmeter (MDL 1401,
Scalar). This provided an accurate (0.0-40.0 mL/min) digital read-
out of mean CF, with a simultaneous hard copy recording through
a connection with a chart recorder (RS3400; Gould Electronics,
Hainault, Essex, United Kingdom). This allowed accurate moni-
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TABLE 1.  Baseline preischemic variables for each group of experiments
Langendorff mode Working mode
n CF (mL/min) Significance n AF (mL/min) CF (mL/min) CO (mL/min) PAP (cm H2O) dP/dt Significance
Control 6 12.3 ± 1.9 6 27.3 ± 8.6 24.3 ± 9.3 51.7 ± 6.7 159 ± 19 18.7 ± 5.3
PD155080 6 13.6 ± 1.6 NS 6 24.6 ± 8.0 25.8 ± 7.2 50.4 ± 6.6 150 ± 11 12.3 ± 4.5 All NS
Control 6 12.5 ± 2.0 5 25.3 ± 4.8 24.0 ± 1.5 49.3 ± 6.1 200 ± 39 75.8 ± 20.6
Ro61-0612 6 12.3 ± 1.3 NS 5 20.4 ± 9.4 25.7 ± 1.5 46.1 ± 9.8 160 ± 30 62.8 ± 24.0 All NS
Control 15 11.3 ± 1.5 6 27.0 ± 8.2 26.4 ± 4.5 53.4 ± 10.1 147 ± 22 13.3 ± 8.3
Bosentan 15 11.8 ± 1.7 NS 6 31.3 ± 6.7 26.4 ± 5.2 57.8 ± 7.1 158 ± 12 16.3 ± 4.1 All NS
Control 6 11.8 ± 1.0 5 27.4 ± 8.6 21.4 ± 4.7 48.8 ± 12.8 155 ± 19 19.2 ± 10.1
BQ788 6 11.6 ± 2.0 NS 5 34.2 ± 7.3 28.2 ± 5.7 62.4 ± 9.2 158 ± 7 13.6 ± 3.8 All NS
Control 5 13.2 ± 1.2 10 25.9 ± 8.4 23.1 ± 5.1 49.0 ± 12.1 164 ± 23 74.2 ± 27.5
Phosphoramidon 5 13.0 ± 1.1 NS 8 23.3 ± 4.9 24.8 ± 6.3 48.0 ± 3.9 153 ± 19 64.5 ± 27.2 All NS
Values are given as means ± standard deviation. Significance is shown versus each respective control group. CF, Coronary flow; AF, aortic flow; PAP, peak
aortic pressure; NS, not significant.
Figure 1. Experimental time course. Shaded area corresponds to
period of cardioplegic arrest at 4°C. LM, Langendorff mode; WM,
working mode.
Goodwin et al Cardiopulmonary Support and Physiology
TX
ET
CS
P
A
CD
CH
D
G
TS
ED
IT
O
RI
A
L
toring of steady-state conditions (less than 0.1 mL/min change in
CF over 3 minutes). While the heart was in working mode, the AF
was measured by means of an electromagnetic flow probe (ECM2
100 mL, Scalar). This allowed measurement of flows from 0 to 100
mL/min. CF (during working mode) was recorded by means of
timed collection of the coronary sinus effluent into a measuring
cylinder. Cardiac output is taken as the sum of AF and CF. Aortic
pressure is measured with a transducer, and a simultaneous hard
copy is made (as above). From this, dP/dt is computed.
Ischemic cardioplegic arrest may be achieved by infusing 10
mL of St Thomas’ Hospital No. 1 solution (made up in 1 L of
Ringer’s lactate solution) at 4°C through the side arm of the aortic
cannula from a reservoir 60 cm above the heart. The heart is then
maintained immersed in cardioplegic solution at 4°C for 4 hours.
This protocol mimics conditions of the donor heart undergoing
cardiac transplantation.
Drugs and Chemicals
The drugs used in this experiment were all made up to the required
concentration in the Krebs buffer. The drugs used were bosentan
(Ro47-0203, 10–5 mol/L; Hoffmann-La Roche Ltd, Basel,
Switzerland), a mixed ETA/ETB antagonist; Ro61-0612 (10–5
mol/L, Hoffmann-La Roche), a mixed ETA/ETB antagonist;
PD155080 (10–4 mol/L; Parke-Davis Pharmaceuticals, Ann Arbor,
Mich), a selective ETA receptor antagonist; BQ788 (10–5 mol/L,
Parke-Davis), a selective ETB antagonist; and phosphoramidon
(10–5 mol/L; Sigma, Poole, Dorset, United Kingdom), an endothe-
lin-converting enzyme (ECE) inhibitor. The concentrations used
were chosen after previous similar experiments in which dose-
response studies were performed.1
Experimental Time Course
Data on the experimental time course are shown in Figure 1.
Low coronary reflow. After excision of the heart, Langendorff
perfusion was commenced with Krebs solution. When steady-state
CF was achieved, the hearts underwent 4 hours of cardioplegic
arrest at 4°C. After ischemia, the hearts were randomly reperfused
with either the drug (experimental group) or Krebs solution (con-
trol group) for 30 minutes (or 60 minutes in the case of phospho-
ramidon). The longer perfusion time for phosphoramidon was cho-
sen because it acts by inhibiting the conversion of big ET to ET. In
a study on human forearm blood flow, a maximum response to
phosphoramidon was seen at 60 minutes.14 Separate controls were
used for each drug. CF was recorded at 5-minute intervals.
Working mode. After excision of the heart, Langendorff perfu-
sion was commenced with Krebs solution. After 15 minutes, the
heart was switched to working mode. At the end of 15 minutes of
working mode, CF, AF, cardiac output, peak aortic pressure, and
dP/dt were recorded. The hearts then underwent 4 hours of cardio-
plegic arrest at 4°C. After ischemia, the hearts were reperfused with
either the drug (experimental group) or Krebs solution (control
group) for 15 minutes in Langendorff mode. Separate controls were
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Figure 2. Effect of different ET antagonists (bosentan and Ro61-0612 = mixed ETA/ETB; PD155080 = ETA; BQ788 =
ETB) on recovery of CF after 4 hours’ cardioplegic arrest at 4°C. *P < .05 versus control.
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used for each drug. After this period of Langendorff perfusion, the
heart was switched back to working mode for a further 15 minutes.
At the end of this period, the same parameters as before were mea-
sured (CF, AF, cardiac output, peak aortic pressure, and dP/dt).
High-Performance Liquid Chromatography Analysis
In the experiment measuring low coronary reflow after the addition
of Ro61-0612, the hearts were freeze-clamped at the end of reper-
fusion. The corresponding control hearts (ie, hearts reperfused
with plain Krebs solution) were also freeze-clamped at the end the
experiment. Tissue extracts were prepared from freeze-dried hearts
with 0.6 mol/L perchloric acid (25 µL/mg dry tissue). The extracts
were then centrifuged (13,000g for 3 minutes at 4°C), and the
supernatant was neutralized with 2 mol/L KOH. All determinations
of metabolite concentrations were performed with high-perfor-
mance liquid chromatography by means of a Merck-Hitachi chro-
matograph (Darmstadt, Germany), as described previously.15-17
Expression of Results
CF, AF, and cardiac output were recorded in milliliters per minute.
Peak aortic pressure was recorded in centimeters of H2O. CFs are
expressed as a percentage of the initial (preischemic) steady-state
CF. In the working mode hearts the postischemic values of cardiac
output, peak aortic pressure, and dP/dt are expressed as a percent-
age of the preischemic values. Data were compared by analysis of
variance, followed by a Bonferroni test for multiple comparisons
to indicate differences between groups.
Results
Low Coronary Reflow
Data on low coronary reflow are shown in Figures 2 and 3.
Baseline preischemic CF for each experimental group is
shown in Table 1. During reperfusion, there was a consistent
decrease in CF in control animals to approximately 85% to
90% of preischemic flow. Reperfusion after the addition of
the combined ETA/ETB antagonists bosentan or Ro61-0612
reversed this decrease and resulted in a further significant
increase in the recovery of postischemic CF (100.9% vs
85.3% [P = .03] and 122.4% vs 83.7% [P < .001], respec-
tively, vs control hearts at 30 minutes of reperfusion). The
addition of the selective ETA antagonist PD155080 had a
similar effect (129.5% vs 91.4% [P = .008]). However, the
addition of BQ788 (ETB antagonist; 84.7% vs 87.4%) and
phosphoramidon (ECE inhibitor; 89.4% vs 88.3% at 60
minutes of reperfusion) had no effect on the recovery of CF.
Recovery of Cardiac Mechanical Function
Data on recovery of cardiac mechanical function are shown
in Figure 4. Baseline preischemic values for each of the
groups are shown in Table 1. When each antagonist was
compared with control solution, there was no significant dif-
ference in the recovery of any of the parameters (cardiac
output, peak aortic pressure, and dP/dt) of cardiac mechan-
ical function. Likewise, the ECE inhibitor phosphoramidon
had no effect on the recovery of mechanical function.
High-Performance Liquid Chromatography
The results of the various metabolites measured are shown
in Table 2. There was a significant increase in adenosine
triphosphate (ATP) levels by 12.1% after reperfusion with
Ro61-0612 (ETA/ETB antagonist) compared with that seen
in control hearts. There were no significant differences in
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TABLE 2. Metabolite concentrations of the heart after 4
hours’ cardioplegic arrest at 4°C and reperfusion with
either Ro61-0612 or Krebs solution (controls)
Control (µmol/g Ro61-0612 (µmol/g
Metabolite dry weight) dry weight)
GTP 0.99 ± 0.01 1.04 ± 0.02
GDP 0.24 ± 0.01 0.22 ± 0.01
GMP 0.22 ± 0.06 0.24 ± 0.03
IMP 0.01 ± 0.01 0.01 ± 0.01
ATP 16.19 ± 0.51 18.14 ± 0.39*
ADP 3.47 ± 0.20 3.28 ± 0.08
AMP 0.29 ± 0.02 0.25 ± 0.02
ADPR 0.13 ± 0.01 0.13 ± 0.01
Hypoxanthine 0.04 ± 0.01 0.04 ± 0.01
Xanthine 0.06 ± 0.03 0.09 ± 0.03
NADP 0.55 ± 0.01 0.49 ± 0.09
NAD 3.95 ± 0.05 4.13 ± 0.08
Uridine 0.001 ± 0.001 0.001 ± 0.001
Inosine 0.08 ± 0.01 0.09 ± 0.01
Adenosine 0.01 ± 0.0 0.02 ± 0.01
GTP, Guanosine triphosphate; GDP, guanosine diphosphate; GMP, guano-
sine monophosphate; IMP, inosine 5´-monophosphate; ADP, adenosine
diphosphate; AMP, adenosine monophosphate; ADPR, adenosine diphos-
phate ribose; NADP, nicotinamide adenine dinucleotide phosphate; NAD,
nicotinamide adenine dinucleotide.
*P = .01 versus control hearts.
Figure 3. Effect of phosphoramidon (ECE inhibitor) given during 60
minutes of reperfusion on the recovery of CF after 4 hours’ cardio-
plegic arrest.
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the levels of the other metabolites measured between the 2
groups.
Discussion
This study has shown that the recovery of CF is significant-
ly improved after the addition of an ET antagonist during
reperfusion. We have demonstrated that both the mixed
ETA/ETB antagonists and selective ETA antagonists had a
beneficial effect, whereas the ETB antagonist had no effect.
This suggests that endogenous ET plays a significant role in
the regulation of coronary tone during reperfusion and that
these effects are mediated through ETA receptors. In addi-
tion, there was a significant increase in ATP levels by 12%
after reperfusion with an ETA/ETB antagonist. Despite the
improvement in CF and ATP levels, we were unable to
demonstrate any beneficial effect on the recovery of cardiac
mechanical function in this model.
A number of investigators have suggested that basal vas-
cular tone may be due to a balance between the release of
vasoconstrictor and vasodilator substances by the endotheli-
um.1,18-21 We have previously demonstrated that endoge-
nous ET plays a role in the basal regulation of coronary tone
in the isolated rat heart mediated through ETA receptors.1
This study has demonstrated for the first time that endoge-
nous ET plays an important role in the regulation of coro-
nary tone during reperfusion. In the experiments with phos-
phoramidon (ECE inhibitor), there was no effect on CF,
despite a prolonged period of reperfusion, suggesting that
de novo ET synthesis during reperfusion does not appear to
play a role in this model. ET levels are increased after warm
ischemia,5 whereas there was no increase in ET release from
lambs’ hearts after 2 hours of hypothermic cardioplegic
arrest, suggesting that ET synthesis may not be possible
during ischemia at low temperatures.22 However, we have
shown previously that an ECE inhibitor given during
ischemia can improve the postischemic recovery of CF.12
These differing results may be due to the different animal
models and ischemic protocols studied.
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 6   1171
Figure 4. Effect of different ET antagonists and phosphoramidon given during reperfusion on the recovery of car-
diac mechanical function after 4 hours’ cardioplegic arrest. CO, Cardiac output; PAP, peak aortic pressure.
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A number of previous studies have used ET antagonists to
examine the role of ET-1 during ischemia and reperfusion.
The results of these studies have been conflicting. Some
studies have shown a beneficial effect on the recovery of car-
diac function,22-26 whereas others have not.11,27 Some stud-
ies have shown improvement in the recovery of CF but not in
function.12 One possible explanation is that ET blockade
removes both the beneficial (positive inotrope) and detri-
mental (vasoconstriction) effects of ET released during and
after ischemia. ET release during ischemia occurs in all
mammalian species studied, including human subjects.
Therefore, it is probable that there is a beneficial role for ET
during ischemia and reperfusion. Possible roles are the main-
tenance of systemic blood pressure during acute hemorrhag-
ic shock, with the diversion of blood flow away from nonvi-
tal organs, and any inotropic effects on the myocardium.
Local release of ET may also divert blood flow away from
infarcted and necrotic areas of myocardium. It has been
shown that the vasoconstrictor effects of exogenous ET-1 are
increased after prolonged cold cardioplegic arrest.28 It has
also been suggested that ET reduces the incidence of malig-
nant cardiac arrhythmias during reperfusion.29,30
We have shown that reperfusion with an ETA/ETB antag-
onist can improve the recovery of ATP levels after pro-
longed ischemia and reperfusion. This would imply that the
use of an ET antagonist may be expected to be of benefit on
cardiac recovery. We were, however, unable to demonstrate
any functional benefit of this metabolic change. The major-
ity of studies demonstrate good correlation between ATP
level and function,17,31,32 but there are situations in which a
lack of such correlation has been clearly demonstrated.33 It
is possible that the observed increase in cardiac ATP levels
were insufficient to obtain any measurable benefit.
Alternatively, the loss of any direct actions of ET-1 on car-
diac function may counteract any beneficial effects seen.
Despite the fact that elevated ATP levels did not translate
into functional improvement, it is possible that they may
provide long-term beneficial effects in vivo by enhancing
endogenous adenosine production34 and by inhibition of
inflammatory and thrombotic mechanisms of reperfusion
injury not reproduced in our present experiments.
In experiments with isolated human left ventricular
myocytes, exogenous ET increased contractility under basal
conditions but reduced contractility after simulated cardio-
plegic arrest.35,36 This would again suggest that ET block-
ade may be beneficial during reperfusion, even though it
was not possible to demonstrate this in our model. Further
studies are required in which CF is maintained at a constant
level during reperfusion to distinguish effects caused by
improvements in CF and direct effects on the myocardium
of circulating ET.
There are a number of limitations to this study. First, a
crystalloid perfused isolated heart does not accurately rep-
resent the normal conditions experienced by the heart in
vivo. However, the benefits of an isolated system are that it
reduces any confounding factors, such as circulating levels
of catecholamines, neuronal control, and any effects caused
by neutrophil-endothelial cell interactions. Second, this
study was performed on rats. Further studies are required to
see whether similar effects are seen in human subjects and
other animals. Finally, the data may only be applicable to
the transplant situation (isolated heart, 4 hours at 4°C),
whereas the conditions during routine cardiac operations
might differ (collateral CF, 1-2 hours at 10°C).
In summary, we conclude that endogenous ET plays a
role in low coronary reflow after prolonged cardioplegic
arrest, mediated through ETA receptors, in a model mimic-
king the conditions of preservation during cardiac opera-
tions. ET blockade during reperfusion also improves the
recovery of high-energy phosphates. These results may have
important implications for clinical practice.
We thank Parke-Davis Pharmaceuticals, Ann Arbor, Michigan,
and Hoffmann-La Roche, Ltd, Basel, Switzerland, for the donation
of the antagonists.
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